Biogen Inc., of Cambridge, Mass., and Swedish Orphan Biovitrum AB, of Stockholm, said interim data from the ASPIRE phase III, open-label extension study were published in Haemophilia, showing that patients on extended-interval prophylaxis regimens with Eloctate (antihemophilic factor [recombinant], Fc fusion protein) experienced low bleeding rates.